Skip to Content
Print Share

Generic Uceris Availability

Uceris is a brand name of budesonide, approved by the FDA in the following formulation(s):

UCERIS (budesonide - aerosol, foam;rectal)

  • Manufacturer: VALEANT PHARMS INTL
    Approval date: October 7, 2014
    Strength(s): 2MG/ACTUATION [RLD]

UCERIS (budesonide - tablet, extended release;oral)

  • Manufacturer: SALIX
    Approval date: January 14, 2013
    Strength(s): 9MG [RLD] [AB]

Has a generic version of Uceris been approved?

A generic version of Uceris has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Uceris and have been approved by the FDA:

budesonide tablet, extended release;oral

  • Manufacturer: ACTAVIS LABS FL INC
    Approval date: July 3, 2018
    Strength(s): 9MG [AB]

Note: No generic formulation of the following product is available.

  • budesonide - aerosol, foam;rectal

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uceris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 10,064,878
    Issued: September 4, 2018
    Assignee(s): COSMO TECHNOLOGIES LTD.

    The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 10,105,374
    Issued: October 23, 2018
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 10,143,698
    Issued: December 4, 2018
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 7,410,651
    Issued: August 12, 2008
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Ajani; Mauro & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 7,431,943
    Issued: October 7, 2008
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Fossati; Mauro Ajani & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,293,273
    Issued: October 23, 2012
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Ajani; Mauro & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,784,888
    Issued: July 22, 2014
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,895,064
    Issued: November 25, 2014
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste making oral pharmaceutical composition
    Patent 9,132,093
    Issued: September 15, 2015
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 9,192,581
    Issued: November 24, 2015
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 9,320,716
    Issued: April 26, 2016
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical compositions
    Patent 9,532,954
    Issued: January 3, 2017
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent RE43799
    Issued: November 13, 2012
    Inventor(s): Villa; Roberto & Pedrani; Massimo & Ajani; Mauro & Fossati; Lorenzo
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • June 9, 2020
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide